[Clinical evaluation of Cernilton in benign prostatic hypertrophy].
Twenty patients with benign prostatic hypertrophy were treated with Cernilton, 6 tablets a day for an average of 13.2 weeks. Subjective effectiveness was observed in the improvement of sense of residual urine (92%), retardation (86%), night frequency (85%), strain on urination (56%), protraction (53%) and forceless urinary stream (53%). The overall subjective effectiveness was 80% of patients, and the overall objective effectiveness was 54% of patients. Night frequency, residual urine volume and tidal urine volume were improved significantly. The overall effectiveness was 80%. No side effects were observed.
Hayashi
J
J
Mitsui
H
H
Yamakawa
G
G
Suga
A
A
Kai
A
A
Shimabukuro
T
T
Yanagi
K
K
Fujisawa
S
S
Takihara
H
H
Kaneda
Y
Y
D000368:Aged; D006801:Humans; D008297:Male; D008875:Middle Aged; D010936:Plant Extracts / Q000627:therapeutic use; D011058:Pollen; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D012434:Secale
D010936:Plant Extracts; C010070:cernilton